Francesco Massari, MD, MSc, PhD, EMBA
Clinical Associate Professor
Boston Medical Center
Radiology

MD, University of Rome
PhD, University of Rome
MSc, University of Rome


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Website       Copy PMIDs To Clipboard

  1. Melotti S, Ambrosi F, Franceschini T, Giunchi F, Vasuri F, Orsatti A, Di Sciascio L, Grillini A, Franchini E, Massari F, Mollica V, Marchetti A, Mineo Bianchi F, Colecchia M, Acosta AM, Lobo J, Fiorentino M, Ricci C. Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors. Am J Clin Pathol. 2025 Nov 19; 164(5):739-745. PMID: 40972670
     
  2. Rizzo A, Zayed A, Vitale E, Buti S, Takeshita H, Crabb S, Roviello G, Seront E, Tapia JC, Scagliarini S, Popovic L, Kopp RM, Abahssain H, Rizzo M, Monteiro FSM, Massafra R, Brunetti O, Santini D, Ürün Y, Montironi R, Mollica V, Massari F, Soares A, Santoni M. Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset. Clin Exp Metastasis. 2025 Sep 06; 42(5):52. PMID: 40913633
     
  3. Aguzzi C, De Summa S, Molina-Cerrillo J, Alonso-Gordoa T, Nabissi M, Rizzo M, Zeppellini A, Sunela K, Sorgentoni G, Ortega C, Massari F, Marques Monteiro FS, Battelli N, Porta C, Santoni G, Santoni M. mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1a). Biochem Biophys Rep. 2025 Sep; 43:102162. PMID: 40821906; PMCID: PMC12354808; DOI: 10.1016/j.bbrep.2025.102162;
     
  4. Rizzo M, Soares A, Gupta S, Calabrò F, Takeshita H, Bourlon MT, Park SH, Giannatempo P, Myint ZW, Büttner T, Grande E, Fiala O, Santini D, Bamias A, Zakopoulou R, Buti S, Kanesvaran R, Rescigno P, Molina-Cerrillo J, Epstein I, Marques Monteiro FS, Massari F, Porta C, Bellmunt J, Santoni M. Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study. JCO Glob Oncol. 2025 Jul; 11:e2400564. PMID: 40627820
     
  5. Santoni M, Roviello G, Grande E, De Giorgi U, Fiala O, Seront E, Molina-Cerrillo J, Pichler R, Myint ZW, Kucharz J, Kanesvaran R, Büttner T, Pichler M, Basso U, Kopecky J, Bourlon MT, Cerbone L, Buchler T, Pinto A, de Liaño AG, Gianni C, Zgura A, Rescigno P, Ansari J, Caffo O, Küronya Z, Vitale MG, Bhuva D, Catalano M, Vau N, Kopp RM, Buti S, Bamias A, Porta C, Sunela K, Massari F. Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Cancer Immunol Immunother. 2025 May 27; 74(7):225. PMID: 40423789; PMCID: PMC12116974; DOI: 10.1007/s00262-025-04043-x;
     
  6. Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, Danielli L, Maloberti T, Ricci C, Fiorentino M, Biase D, Massari F. Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience. Pathol Res Pract. 2025 Jun; 270:155964. PMID: 40233528
     
  7. Danielli L, Tassinari E, Marchetti A, Rosellini M, Mollica V, Cheng L, Massari F. Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges. Expert Rev Anticancer Ther. 2025 May; 25(5):457-470. PMID: 40089934
     
  8. Incorvaia L, Scagliarini S, Marques Monteiro FS, Takeshita H, Tapia JC, Gandur Quiroga MN, Lam E, Tural D, Popovic L, Campos-Gomez S, Zucali PA, Mota A, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Abahssain H, Galosi AB, Badalamenti G, Kopecky J, Bamias A, Landmesser J, Ansari J, Calabrò F, Massari F, Buti S, Bellmunt J, Santoni M. Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab. Sci Rep. 2025 Mar 14; 15(1):8815. PMID: 40087324; PMCID: PMC11909119; DOI: 10.1038/s41598-025-93094-2;
     
  9. Giudice GC, Maffezzoli M, Testi I, Acunzo A, Agnetti V, Tuttobene P, Donini M, Massari F, Mollica V, Rizzo A, Buti S. Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review. Expert Rev Anticancer Ther. 2025 Feb 10. PMID: 39930832
     
  10. Rizzo A, Monteiro FSM, Mollica V, Soares A, Brunetti O, Ricci AD, Massari F, Santoni M. Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis. Clin Exp Metastasis. 2024 Dec 16; 42(1):3. PMID: 39680251
     
Showing 10 of 246 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 246 publications over 22 distinct years, with a maximum of 32 publications in 2022

YearPublications
20031
20045
20052
20062
20072
20082
20095
20103
20122
20133
201410
201520
201617
201724
201821
201923
202026
202118
202232
202311
20248
20259


2021 International Conference Society of Interventional Radiological (SIR) 2021: SIR 2021 ABSTRACT OF THE YEAR
2012 American Society of Spine Radiology Congress: ASSR COMMITTEE AWARD
Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map


Massari's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Similar People
_
Same Department